Lymphoma

Latest News

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.
Acalabrutinib Earns FDA Priority Review in Untreated Mantle Cell Lymphoma

October 3rd 2024

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility

September 23rd 2024

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.
Azer-Cel Achieves Complete Responses in Relapsed/Refractory DLBCL

September 18th 2024

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.
Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

September 10th 2024

Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.
Data Support Increased Subcutaneous Rituximab Use in Non-Hodgkin Lymphoma

September 6th 2024